Page 44 - Exact Sciences News Today

Exact Sciences (NASDAQ:EXAS – Get Rating) had its target price increased by analysts at Benchmark from $81.00 to $96.00 in a research note issued to investors on Thursday, The Fly reports. Benchmark’s target price indicates a potential upside of 3.65% from the stock’s previous close. Several other analysts have also recently issued reports on the […]

Exact Sciences Co. (NASDAQ:EXAS – Get Rating) – SVB Leerink increased their Q2 2023 earnings per share estimates for Exact Sciences in a research note issued to investors on Tuesday, June 20th. SVB Leerink analyst P. Souda now anticipates that the medical research company will post earnings per share of ($0.50) for the quarter, up […]

"We certainly think it's got significant growth in front of it," fund manager Dani Saurymper told Pro Talks of one diagnostics stock.

Traynor Capital Management Inc. raised its holdings in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 61.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,528 shares of the medical research company’s stock after purchasing an additional 9,706 shares […]

1-800-FLOWERS.COM reissued their reiterates rating on shares of Exact Sciences (NASDAQ:EXAS – Get Rating) in a research note released on Thursday, Benzinga reports. Other research analysts have also recently issued reports about the stock. Cowen lifted their price target on shares of Exact Sciences from $56.00 to $76.00 and gave the company an outperform rating […]

Canaccord Genuity has decided to maintain its Buy rating of Exact Sciences (NASDAQ:EXAS) and raise its price target from $92.00 to $115.00. Shares...

Laura Nuttall, diagnosed with deadly brain cancer at age 18, completed an incredible bucket list before dying at 23, sparking the question of whether earlier detection through blood tests could have saved her life.

Tuesday, Exact Sciences Corp (NASDAQ: EXAS) announced topline results from the pivotal BLUE-C study, showing that next-generation 

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero